Diabetes
Refine Search
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Sumitomo Dainippon Pharma has entered into a strategic collaboration with French diabetes-focused biotech firm Poxel for the development and commercialization of imeglimin. 30 October 2017
Pharmaceutical
The share price of US pharma giant Merck & Co was down 5% by lunchtime on Friday at $58.74. 27 October 2017
Generics
Amid falling sales of its leading diabetes product Lantus (insulin glargine) due to generic competition, French pharma major Sanofi is taking further legal action in the USA. 25 October 2017
Pharmaceutical
Eli Lilly reported revenue and earnings figures for the third quarter of 2017 that narrowly exceeded the expectations of Wall Street analysts on Tuesday. 24 October 2017
Pharmaceutical
Nobody is surprised now when pharma companies that are presenting data at scientific conferences choose to focus on real-world evidence (RWE) as much as, or more than, on their results from randomized control trials. 20 October 2017
Pharmaceutical
The incidence of diabetes mellitus (DM), and most notably type 2 diabetes mellitus (T2DM), which accounts for 90–95% of all DM cases, is growing rapidly on a global scale. 16 October 2017
Pharmaceutical
French pharma major Sanofi today announced the appointment of Stefan Oelrich as executive vice president Diabetes & Cardiovascular (DCV), effectively immediately. 2 October 2017
Pharmaceutical
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has endorsed an update of the European Union label with immediate effect for Tresiba (insulin degludec) to include results from the DEVOTE trial on severe hypoglycemia. 29 September 2017
Pharmaceutical
Danish diabetes care giant Novo Nordisk today announced that the China Food and Drug Administration (CFDA) has approved Tresiba (insulin degludec) for the treatment of diabetes in China, which it said has the world's highest number of adult diabetes patients. 27 September 2017
Pharmaceutical
AstraZeneca had an active time yesterday at the 53rd annual meeting of European Association for the Study of Diabetes (EASD), presenting favorable new data on two of its already marketed diabetes treatments, Bydureon (exenatide extended-release) and Farxiga (dapagliflozin). 15 September 2017
Pharmaceutical
New analyses of the landmark EMPA-REG OUTCOME trial showed that Jardiance (empagliflozin) reduced the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular (CV) disease, independent of blood sugar control at the start of the study. 13 September 2017
Pharmaceutical
In certain adults with type 2 diabetes, Soliqua 100/33 (insulin glargine and lixisenatide injection, 100 Units/mL & 33 mcg/mL) provided blood sugar control earlier and in more adults than those treated with insulin glargine 100 Units/mL alone, according to a new post-hoc analysis of key late-stage clinical trials. 12 September 2017
Pharmaceutical
Fiasp (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting mealtime insulin, improved overall blood sugar (HbA1c) and post-meal sugar (postprandial glucose or PPG) control over 52 weeks, compared to conventional insulin aspart (NovoRapid), in new study findings. 12 September 2017
Generics
Biocon’s subsidiary in Malaysia, Biocon Sdn Bhd, has been issued a certificate of ´GMP Compliance´ for its insulins manufacturing facility by the HPRA (Ireland) as the representative European Union inspection authority. 8 September 2017
Pharmaceutical
Novo Nordisk will pay $58.65 million to resolve allegations that the company failed to comply with the Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) for its top-selling type 2 diabetes medication Victoza (liraglutide), the Justice Department announced yesterday. 6 September 2017
Pharmaceutical
Janssen Pharmaceutica has entered into an exclusive distribution agreement for diabetes treatments Invokana (canagliflozin) and Vokanamet (a fixed-dose combination of canagliflozin and metformin) in countries in the European Economic Area (EEA) and Switzerland where the products have obtained pricing and reimbursement approvals. 5 September 2017
Generics
The US Food and Drug Administration on Friday granted tentative approval for Admelog (insulin lispro injection) 100 Units/mL, a rapid-acting human insulin analogue. 4 September 2017
Pharmaceutical
Japanese drug major Daiichi Sankyo, and its US subsidiary, have elected to terminate its 2014 development and commercialization agreement with Charleston Laboratories 31 August 2017
Biosimilars
The global biosimilars market is expected to reach a value $13.1 billion by 2024 on account of increase in the prevalence of chronic diseases such as cancer, diabetics, cardiac disorders and autoimmune diseases. 31 August 2017
Pharmaceutical
An analysis presented at the European Society of Cardiology (ESC) Annual Congress has shown that Victoza (liraglutide) reduces the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of whether they have had a heart attack or stroke or not. 29 August 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze